Researchers led by James Tumlin presented updated data based on longer follow-up from the RUBY-3 phase 1b/2a study of povetacicept in an abstract at the International Society of Nephrology World Congress of Nephrology 2024. Initial results of RUBY-3 found that povetacicept 80 mg given subcutaneously once every 4 weeks showed good tolerability with multiple dosing and promising reductions in urine protein-to-creatinine ratio (UPCR) and galactose-deficient IgA1 (Gd-IgA1) in study participants with immunoglobulin A nephropathy (IgAN). ...
Nephrology Times
Nephrology Times delivers the latest news in kidney-related treatments and technologies with the goal of better informing care decisions and improving patient outcomes.
Advertisement
Latest News
Researchers uncovered clinical and economic of the Kidney BEAM physical activity digital health intervention for CKD.
A study examined the risk factors, prevalence, and impact of pruritus associated with CKD in hemodialysis patients.
Researchers found that sparsentan had a clinically meaningful benefit on long-term kidney preservation versus irbesartan.
Outset Medical has joined the American Nephrology Nurses Association's Partnership Advisory Council.
Researchers studied the prevalence of hyperkalemia in patients at a facility in Durban, South Africa.
Use of antidepressants among patients with CKD is widespread but few data are available on their safety in this population.
Researchers reported on real-world use of SZC for hyperkalemia in a cohort of Asian hemodialysis patients.
The AAKP awarded Dr. Barry Smith the 2024 Medal of Excellence Award in the physician category.
Few data are available on the role of statins for preventing ASCVD in patients with moderate chronic kidney disease.
A simulation model predicts a dramatic increase in the impact of chronic kidney disease in the next 10 years.
Advertisement
In Print
Assessing recurrent gout risk, SARS-CoV-2 vaccine response during dialysis, plant-based diets with CKD, and more.
Special issue discusses racial inequity in living donor kidney transplant, teen BMI and CKD risk, and more
Conferences
The annual scientific, educational, and networking meeting of the International Society of Nephrology
The American Society of Nephrology's annual meeting to highlight the latest scientific and medical advances in the field
The National Kidney Foundation's premier educational event covering advancements in all subspecialties of nephrology
The joint annual meeting of the American Society of Transplantation and the American Society of Transplant Surgeons
Expert Columns
Medicare Advantage plans are posing significant operational and financial hurdles for dialysis programs.
APRIL has emerged as a critical factor in the pathogenesis of IgAN and is the focus of several clinical development programs.
The benefit-risk ratio and considerations about unmet need are worth considering.
The choice of a billing solution, often made under the guise of cost savings, requires a thoughtful approach.
The new base rate for CY 2024 is set at $271.02, which is a 2% increase from CY 2023.
SGLT2i therapy is contraindicated in patients with type 1 diabetes mellitus (T1DM) who have CKD.
Advertisement
Advertisement
Nephrology Times Chair
Ajay K. Singh, MBBS, FRCP, MBASenior Nephrologist, Brigham and Women’s Hospital | Senior Associate Dean, Harvard Medical School
Editorial Board
Mohamed G. Atta, MD, MPHProfessor of Medicine, Johns Hopkins School of Medicine
Timothy E. Bunchman, MDProfessor and Director, Pediatric Nephrology, Transplantation, and Rheumatology, Children’s Hospital of Richmond at VCU
Suphamai Bunnapradist, MD, MSProfessor of Medicine, David Geffen School of Medicine at UCLA | Research Director, Kidney Transplant Program, UCLA
Fernando C. Fervenza, MD, PhDProfessor of Medicine, Division of Nephrology and Hypertension, Mayo Clinic
Kenneth A. Liss, DOPartner, Hypertension and Nephrology Association, Eatontown, NJ
Joel M. Topf, MD, FACPAssistant Clinical Professor of Medicine, Oakland University William Beaumont School of Medicine
